Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.48 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.37 |
| ▸ | SRC | P12931 | 8/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9918105 | 1.00 | NR1H2 (0.48) | NR1H2CHRM2CHRM1CHRM3SRC | |
| SCHEMBL25323350 | 1.00 | NR1H2 (0.48) | NR1H2CHRM2CHRM1CHRM3SRC | |
| SCHEMBL9918104 | 0.88 | NR1H2 (0.42) | NR1H2CHRM2CHRM1CHRM3USP2 | |
| SCHEMBL8007592 | 0.86 | NR1H2 (0.40) | NR1H2CHRM2CHRM1CHRM3SRC | |
| SCHEMBL12216558 | 0.86 | NR1H2 (0.49) | NR1H2CHRM2CHRM1CHRM3SRC | |
| SCHEMBL3442167 | 0.86 | NR1H2 (0.49) | NR1H2CHRM2CHRM1CHRM3SRC | |
| SCHEMBL116328 | 0.86 | NR1H2 (0.49) | NR1H2CHRM2CHRM1CHRM3SRC | |
| SCHEMBL21232089 | 0.86 | NR1H2 (0.49) | NR1H2CHRM2CHRM1CHRM3SRC | |
| SCHEMBL115983 | 0.86 | NR1H2 (0.49) | NR1H2CHRM2CHRM1CHRM3SRC | |
| SCHEMBL934114 | 0.86 | NR1H2 (0.49) | NR1H2CHRM2CHRM1CHRM3SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250163048-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2025-05-22 | — | — | US | disclosed |
| EP-4469455-A1 | COMPOUNDS AND METHODS OF USE | Tango Therapeutics, Inc. (US) | 2024-12-04 | — | — | EP | disclosed |
| WO-2023146990-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023146990-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250163048-A1 | COMPOUNDS AND METHODS OF USE | RB1, CYP1B1, REN | NR1H2 879/4885CHRM2 894/4885CHRM1 654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.